Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Announces Closing of Share Exchange and Asset Purchase (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza... see more

Recent & Breaking News (NDAQ:AZN)

TAGRISSO® (osimertinib) Granted Breakthrough Therapy Designation by US FDA for the 1st-Line Treatment of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

Business Wire October 9, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  September 22, 2017

The Market In 5 Minutes

Benzinga.com  September 22, 2017

Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile and Fewer CV Events in Patients with Type-2 Diabetes at Wide Range of CV Risk

Business Wire September 14, 2017

The Market In 5 Minutes

Benzinga.com  September 14, 2017

Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson

PR Newswire September 13, 2017

AstraZeneca’s TAGRISSO® (osimertinib) Shows Potential as a New Standard of Care in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer at ESMO 2017 Congress

Business Wire September 8, 2017

AstraZeneca Presents Superior Progression-Free Survival for IMFINZI® (durvalumab) in the Pacific Trial of Patients with Locally-Advanced Unresectable Lung Cancer at ESMO 2017 Congress

Business Wire September 8, 2017

Watch These 8 Huge Call Purchases In Friday Trade

Benzinga.com  September 8, 2017

15 Biggest Mid-Day Gainers For Thursday

Benzinga.com  September 7, 2017

A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Economic Data, Fed Speakers

Benzinga.com  September 7, 2017

Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma

PR Newswire September 6, 2017

Wall Street's M&A Chatter From August 31: Barnes & Noble, Constellium, Daiichi Sankyo

Benzinga.com  September 1, 2017

FASLODEX® (fulvestrant) Receives US FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer

Business Wire August 28, 2017

LYNPARZA® (olaparib) Receives Additional FDA Approval in the US for Ovarian Cancer

Business Wire August 17, 2017